Activation of Expression of Brain-Derived Neurotrophic Factor at the Site of Implantation of Allogenic and Xenogenic Neural Stem (Progenitor) Cells in Rats with Ischemic Cortical Stroke

Chekhonin, V. P.; Лебедев, С. В.; Volkov, A. I.; Павлов, К. А.; Ter-Arutyunyants, A. A.; Volgina, N. E.; Savchenko, Ekaterina; Grinenko, N. F.; Lazarenko, I. P.

doi:10.1007/s10517-011-1180-8

Cited by 8 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experiments have demonstrated that transplanted NSCs exhibit strong plasticity, can easily integrate with host cells and can establish a stable synaptic connection and become functional substituting nerve cells [26-28]. Additionally, NSCs may produce neurotrophic factors that facilitate the recovery of impaired tissues in the diseased brain region [29-32]. Consistent with these findings, we found that autologous NSC-like cells derived from MSCs could differentiate into neuronal and glial lineages in vitro.…”

Section: Discussionsupporting

confidence: 82%

Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy

Chen¹,

Wang²,

et al. 2013

J Transl Med

View full text Add to dashboard Cite

BackgroundStem cell therapy is a promising treatment for cerebral palsy, which refers to a category of brain diseases that are associated with chronic motor disability in children. Autologous MSCs may be a better cell source and have been studied for the treatment of cerebral palsy because of their functions in tissue repair and the regulation of immunological processes.MethodsTo assess neural stem cell–like (NSC-like) cells derived from autologous marrow mesenchymal stem cells as a novel treatment for patients with moderate-to-severe cerebral palsy, a total of 60 cerebral palsy patients were enrolled in this open-label, non-randomised, observer-blinded controlled clinical study with a 6-months follow-up. For the transplantation group, a total of 30 cerebral palsy patients received an autologous NSC-like cells transplantation (1-2 × 107 cells into the subarachnoid cavity) and rehabilitation treatments whereas 30 patients in the control group only received rehabilitation treatment.ResultsWe recorded the gross motor function measurement scores, language quotients, and adverse events up to 6 months post-treatment. The gross motor function measurement scores in the transplantation group were significantly higher at month 3 (the score increase was 42.6, 95% CI: 9.8–75.3, P=.011) and month 6 (the score increase was 58.6, 95% CI: 25.8–91.4, P=.001) post-treatment compared with the baseline scores. The increase in the Gross Motor Function Measurement scores in the control group was not significant. The increases in the language quotients at months 1, 3, and 6 post-treatment were not statistically significant when compared with the baseline quotients in both groups. All the 60 patients survived, and none of the patients experienced serious adverse events or complications.ConclusionOur results indicated that NSC-like cells are safe and effective for the treatment of motor deficits related to cerebral palsy. Further randomised clinical trials are necessary to establish the efficacy of this procedure.

show abstract

Section: Discussionsupporting

confidence: 82%

Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy

Chen¹,

Wang²,

et al. 2013

J Transl Med

View full text Add to dashboard Cite

show abstract

“…Lim et al, 2011;Ma et al, 2012;Makar et al, 2008;Makar et al, 2009). Furthermore, modest endogenous levels of BDNF protein in mesenchymal and neural stem cells (Chekhonin et al, 2011;Li et al, 2006;Mauri et al, 2012) have also been shown to be beneficial on co-cultured neurons (Mauri et al, 2012). Hence, the 8-fold overexpression of functional BDNF-GFP we achieved here is of physiological relevance.…”

Section: Expression Level Of Bdnf-gfp In Escsmentioning

confidence: 67%

Stably BDNF-GFP expressing embryonic stem cells exhibit a BDNF release-dependent enhancement of neuronal differentiation

Leschik

Eckenstaler

Nieweg

et al. 2013

Journal of Cell Science

View full text Add to dashboard Cite

SummaryBrain-derived neurotrophic factor (BDNF) is known to be a crucial regulator of neuronal survival and synaptic plasticity in the mammalian brain. Furthermore, BDNF positively influences differentiation of embryonic neural precursors, as well as that of neural stem cells from adult neurogenic niches. To study the impact of cell-released BDNF on neural differentiation of embryonic stem cells (ESCs), which represent an attractive source for cell transplantation studies, we have generated mouse ESC clones overexpressing BDNF-GFP by use of knock-in technology. After neural differentiation in vitro, we observed that ESC clones overexpressing BDNF-GFP gave rise to an increased number of neurons as compared to control ESCs. Neurons derived from BDNF-GFP-expressing ESCs harbored a more complex dendritic morphology and differentiated into the GABAergic lineage more than controls. Moreover, we show that ESC-derived neurons released BDNF-GFP in an activity-dependent manner and displayed similar electrophysiological properties as cortical neurons. Thus, our study describes the generation of ESCs stably overexpressing BDNF-GFP, which are ideally suited to investigate the ameliorating effects of BDNF in cell transplantation studies of various neuropathological conditions.

show abstract

“…First, MSCs could significantly integrate with neural host cells, establish synaptic connections, and recover nerve cell functions (24)(25)(26). In addition, MSCs could produce some neurotrophic factors facilitating recovery of disturbed neuronal tissues in affected regions (27)(28)(29)(30). In fact, different types of stem cells, such as MSCs, could differentiate into neuronal and glial lineages.…”

Section: Discussionmentioning

confidence: 99%

A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement

et al. 2018

View full text Add to dashboard Cite

The current knowledge on how to use stem cells therapeutically for improving motor function in patients with cerebral palsy is growing. The present review aimed at assessing clinical trials related to beneficial effects of stem cells in patients with cerebral palsy. Electronic searches including "stem cell" and "cerebral palsy" as keywords were conducted using PubMed, Ovid, Web of Science, Scopus, Cochrane library, and CINAHL till February 2016. Two assessors reviewed the methodological quality and eligibility of the retrieved articles, independently. Among 77 studies initially reviewed based on the keywords, only 6 clinical trials were identified that met the inclusion criteria. Pooled response rate of stem cell therapy to treat cerebral palsy was estimated by assessing the percentage of improvement with a gross motor function classification system score. The resulting pooled estimate indicated a 30.7% (95% CI: 25.80% to 35.69%) increase in the score, 1 to 6 months after cell transplantation. In this regard, the test for heterogeneity was statistically significant (I2 = 87.9%, χ 2 = 41.22, P < 0.0001). Stem cell therapy has the potential to improve motor function in patients with cerebral palsy. However, promising results from limited studies warrant further research.

show abstract

Activation of Expression of Brain-Derived Neurotrophic Factor at the Site of Implantation of Allogenic and Xenogenic Neural Stem (Progenitor) Cells in Rats with Ischemic Cortical Stroke

Cited by 8 publications

References 9 publications

Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy

Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy

Stably BDNF-GFP expressing embryonic stem cells exhibit a BDNF release-dependent enhancement of neuronal differentiation

A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement

Contact Info

Product

Resources

About